Irinotecan liposome plus anlotinib for SCLC after first chemo
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have small cell lung cancer that came back or got worse within 6 months after your first platinum-based chemo.
- You have at least one tumor that can be measured on a scan.
- You are physically active enough to do daily activities (ECOG score 0-2).
- Your blood counts, liver, and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two medicines — a chemotherapy called irinotecan liposome and an immunotherapy called ivonescimab — for people whose small cell lung cancer has returned or progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of two drugs—a type of chemotherapy called paclitaxel (in a special micelle formulation, like a tiny carrier) plus an immunotherapy called ivonescimab—for people whose small-cell lung cancer has returned after standard treatment. The goal is to see if this combo can help shrink tumors and slow the cancer's growth.
This study tests a combination of two chemotherapy drugs (irinotecan liposome and a platinum drug) plus an immunotherapy drug and a targeted therapy (anlotinib) as maintenance treatment after initial chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination keeps the cancer from growing for as long as possible.
This trial tests a combination of two drugs for people with extensive-stage small cell lung cancer that has stopped responding to at least two previous treatments. The goal is to see if this combination can help control the cancer when other options have failed.
This trial tests a new combination of drugs, including liposomal irinotecan, as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard options.
Hear when a new Small Cell Lung Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.